Hanyang Med Rev.  2012 Nov;32(4):213-218. 10.7599/hmr.2012.32.4.213.

Recent Advances in Obesity Research and Management

• Lee DH

• KMID: 2168212
• DOI: http://doi.org/10.7599/hmr.2012.32.4.213

Abstract

Obesity is at epidemic proportions worldwide. Obesity is a significant risk factor for cardiovascular disease, diabetes, cancer and other chronic diseases. Initial lifestyle modification may be intended to induce 7-10% decrease in baseline body weight in obese subjects. Drug therapy can be introduced for subjects with a BMI> or =30 kg/m2 or in those with a BMI > or =27 kg/m2 when comorbidities, such as hypertension or type 2 diabetes mellitus, are present. Bariatric surgery is widely available and can be performed for individuals with a BMI > or =40 kg/m2 (or for patients with a BMI> or =35 kg/m2 and comorbidities) who are unsuccessful with other therapies. Recently, many basic research findings showed that inflammatory responses to metabolic dysfunctions are key pathophysiologic changes in obesity and insulin resistance. Further studies will be required to find out effective targets to manage obesity and to resolve various unanswered issues about diet and exercise regimens. Furthermore, more data about bariatric surgeries are required.

Keyword

Obesity; Insulin Resistance; Inflammation; Anti-Obesity Agents; Bariatric Surgery

MeSH Terms

Anti-Obesity Agents
Bariatric Surgery
Body Weight
Cardiovascular Diseases
Chronic Disease
Comorbidity
Diabetes Mellitus, Type 2
Diet
Humans
Hypertension
Inflammation
Insulin Resistance
Life Style
Obesity
Risk Factors
Anti-Obesity Agents

Reference

1. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004. 363:157–163.

2. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012. 307:491–497.

3. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab. 2004. 89:2583–2589.

4. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000. 132:112–117.

5. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterology. 2000. 118:1117–1123.

6. Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, et al. Body weight and mortality among women. N Engl J Med. 1995. 333:677–685.

7. Jousilahti P, Tuomilehto J, Vartiainen E, Pekkanen J, Puska P. Body weight, cardiovascular risk factors, and coronary mortality. 15-year follow-up of middle-aged men and women in eastern Finland. Circulation. 1996. 93:1372–1379.

8. de Koning L, Merchant AT, Pogue J, Anand SS. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur Heart J. 2007. 28:850–856.

9. Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist. 2010. 15:556–565.

10. Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007. 357:753–761.

11. Boden G. Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes. 2011. 18:139–143.

12. De Nardo D, Latz E. NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol. 2011. 32:373–379.

13. Wen H, Gris D, Lei Y, Jha S, Zhang L, Huang MT, et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol. 2011. 12:408–415.

14. Gao Z, Zhang X, Zuberi A, Hwang D, Quon MJ, Lefevre M, et al. Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes. Mol Endocrinol. 2004. 18:2024–2034.

15. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest. 2011. 121:2111–2117.

16. Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M, et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med. 2009. 15:914–920.

17. Fessler MB, Rudel LL, Brown JM. Toll-like receptor signaling links dietary fatty acids to the metabolic syndrome. Curr Opin Lipidol. 2009. 20:379–385.

18. Rubartelli A. Redox control of NLRP3 inflammasome activation in health and disease. J Leukoc Biol. 2012. 92:951–958.

19. Gross O, Thomas CJ, Guarda G, Tschopp J. The inflammasome: an integrated view. Immunol Rev. 2011. 243:136–151.

20. Leemans JC, Cassel SL, Sutterwala FS. Sensing damage by the NLRP3 inflammasome. Immunol Rev. 2011. 243:152–162.

21. Stienstra R, Tack CJ, Kanneganti TD, Joosten LA, Netea MG. The inflammasome puts obesity in the danger zone. Cell Metab. 2012. 15:10–18.

22. Vetter ML, Faulconbridge LF, Webb VL, Wadden TA. Behavioral and pharmacologic therapies for obesity. Nat Rev Endocrinol. 2010. 6:578–588.

23. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002. 346:393–403.

24. Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009. 360:859–873.

25. Bray GA, Ryan DH. Medical therapy for the patient with obesity. Circulation. 2012. 125:1695–1703.

26. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004. 27:155–161.

27. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011. 377:1341–1352.

28. Lam DD, Przydzial MJ, Ridley SH, Yeo GS, Rochford JJ, O'Rahilly S, et al. Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology. 2008. 149:1323–1328.

29. Weissman NJ, Tighe JF Jr, Gottdiener JS, Gwynne JT. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. N Engl J Med. 1998. 339:725–732.

30. Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011. 96:3067–3077.

31. Dumon KR, Murayama KM. Bariatric surgery outcomes. Surg Clin North Am. 2011. 91:1313–1338.

32. Flum DR, Belle SH, King WC, Wahed AS, Berk P, Chapman W, et al. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med. 2009. 361:445–454.

33. Buchwald H, Estok R, Fahrbach K, Banel D, Sledge I. Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery. 2007. 142:621–632.

34. Shi X, Karmali S, Sharma AM, Birch DW. A review of laparoscopic sleeve gastrectomy for morbid obesity. Obes Surg. 2010. 20:1171–1177.

35. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004. 292:1724–1737.